End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
7.79 CNY | -1.02% | -10.46% | +9.10% |
May. 29 | China Approves Lukang Pharma's Anti-Asthma Injection | MT |
Apr. 23 | Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2022 | 5.62B 776M | Sales 2023 | 6.15B 849M | Capitalization | 6.36B 878M |
---|---|---|---|---|---|
Net income 2022 | 138M 19.06M | Net income 2023 | 246M 33.97M | EV / Sales 2022 | 1.53 x |
Net Debt 2022 | 2.16B 299M | Net Debt 2023 | 2.08B 287M | EV / Sales 2023 | 1.37 x |
P/E ratio 2022 |
48.4
x | P/E ratio 2023 |
25.5
x | Employees | 6,484 |
Yield 2022 |
0.69% | Yield 2023 |
1.26% | Free-Float | 73.25% |
1 day | -1.02% | ||
1 week | -10.46% | ||
1 month | +9.10% | ||
3 months | +25.65% | ||
6 months | -2.62% | ||
Current year | +9.10% |
Managers | Title | Age | Since |
---|---|---|---|
Kun Dong
CEO | Chief Executive Officer | 55 | 21-05-18 |
Li Li
DFI | Director of Finance/CFO | 58 | 16-02-29 |
Xin Peng
CHM | Chairman | 51 | 94-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Hao Dong Qi
BRD | Director/Board Member | 64 | 21-05-18 |
Zi Xin Deng
BRD | Director/Board Member | 67 | 21-05-18 |
Xin Peng
CHM | Chairman | 51 | 94-07-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +3.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 7.79 | -1.02% | 62,554,260 |
24-05-30 | 7.87 | -2.60% | 67,897,560 |
24-05-29 | 8.08 | -0.25% | 71,490,040 |
24-05-28 | 8.1 | -2.64% | 85,793,060 |
24-05-27 | 8.32 | -4.37% | 135,687,300 |
End-of-day quote Shanghai S.E., May 30, 2024
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.10% | 964M | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- 600789 Stock